Therapy of experimental herpes simplex encephalitis with aciclovir in mice

N. H. Park, D. Pavan-Langston, S. L. McLean, D. M. Albert

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 hr after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to 1/2 x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-D-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.

Original languageEnglish (US)
Pages (from-to)775-779
Number of pages5
JournalAntimicrobial agents and chemotherapy
Issue number6
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Therapy of experimental herpes simplex encephalitis with aciclovir in mice'. Together they form a unique fingerprint.

Cite this